Financial Tearsheet

Company Overview

Tenax Therapeutics Inc (NASDAQ:TENX)

Tenax Therapeutics is focused on developing and commercializing pharmaceutical products that improve outcomes for patients who require treatment for various critical care conditions. 

Recent Financial News

Stock Performance

Today's Open 1.89
Volume 210,895
Day Range 1.80 - 1.90
52 Week Range 0.52 - 3.68
Bid/Ask 1.85 / 1.82
Bid/Ask Size 6,600 X 600
Previous Close 1.89
Market Cap 51.18 million
Shares Outstanding 28.12 million
Dividend/Yield 0.00 / 0.00%
EPS (TTM) 0.530103
P/E Ratio (TTM) 3.43

Recent XBRL Filings

Filing Date Form Type Description View
Apr 16, 2021 10-K/A Annual report (Amendment) htmlhtml   pdfpdf   xbrlxbrl  
Mar 31, 2021 10-K Annual report htmlhtml   pdfpdf   xbrlxbrl  
Nov 16, 2020 10-Q Quarterly report htmlhtml   pdfpdf   xbrlxbrl  
Aug 14, 2020 10-Q Quarterly report htmlhtml   pdfpdf   xbrlxbrl  
May 15, 2020 10-Q Quarterly report htmlhtml   pdfpdf   xbrlxbrl  

Management Team

Anthony DiTonno, Chief Executive Officer

Michael B. Jebsen, President and Chief Financial Officer

Dr. Stuart Rich, Chief Medical Officer

Nancy Hecox, EVP, Legal Affairs, General Counsel, and Corporate Secretary

Doug Randall, EVP of Commercial and Business Operations

Douglas Hay, PhD, SVP of Regulatory Affairs

Board of Directors

Dr. Ronald Blanck, Chairman

Anthony DiTonno, Chief Executive Officer

James Mitchum, Director

Gregory Pepin, Director

Gerald Proehl, Director

Chris A. Rallis, Director

Steven Boyd, Director

Keith Maher, M.D., Director

Dr. June Almenoff, Director

Dr. Michael Davidson, Director

Dr. Declan Doogan, Director